Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the company said in a business update provided on Thursday.
The company described...